Yokel Robert A, Hussain Salik, Garantziotis Stavros, Demokritou Philip, Castranova Vincent, Cassee Flemming R
Pharmaceutical Sciences, University of Kentucky, US ; Graduate Center for Toxicology, University of Kentucky, US.
Clinical Research Unit, National Institute of Environmental Health Sciences, National Institutes of Health, US.
Environ Sci Nano. 2014 Oct 1;1(5):406-428. doi: 10.1039/C4EN00039K.
This critical review evolved from a SNO Special Workshop on Nanoceria panel presentation addressing the toxicological risks of nanoceria: accumulation, target organs, and issues of clearance; how exposure dose/concentration, exposure route, and experimental preparation/model influence the different reported effects of nanoceria; and how can safer by design concepts be applied to nanoceria? It focuses on the most relevant routes of human nanoceria exposure and uptake, disposition, persistence, and resultant adverse effects. The pulmonary, oral, dermal, and topical ocular exposure routes are addressed as well as the intravenous route, as the latter provides a reference for the pharmacokinetic fate of nanoceria once introduced into blood. Nanoceria reaching the blood is primarily distributed to mononuclear phagocytic system organs. Available data suggest nanoceria's distribution is not greatly affected by dose, shape, or dosing schedule. Significant attention has been paid to the inhalation exposure route. Nanoceria distribution from the lung to the rest of the body is less than 1% of the deposited dose, and from the gastrointestinal tract even less. Intracellular nanoceria and organ burdens persist for at least months, suggesting very slow clearance rates. The acute toxicity of nanoceria is very low. However, large/accumulated doses produce granuloma in the lung and liver, and fibrosis in the lung. Toxicity, including genotoxicity, increases with exposure time; the effects disappear slowly, possibly due to nanoceria's biopersistence. Nanoceria may exert toxicity through oxidative stress. Adverse effects seen at sites distal to exposure may be due to nanoceria translocation or released biomolecules. An example is elevated oxidative stress indicators in the brain, in the absence of appreciable brain nanoceria. Nanoceria may change its nature in biological environments and cause changes in biological molecules. Increased toxicity has been related to greater surface Ce, which becomes more relevant as particle size decreases and the ratio of surface area to volume increases. Given its biopersistence and resulting increased toxicity with time, there is a risk that long-term exposure to low nanoceria levels may eventually lead to adverse health effects. This critical review provides recommendations for research to resolve some of the many unknowns of nanoceria's fate and adverse effects.
这篇批判性综述源自一氧化铈纳米颗粒(nanoceria)毒理学风险的SNO特别研讨会小组报告,内容涉及nanoceria的积累、靶器官和清除问题;暴露剂量/浓度、暴露途径以及实验制剂/模型如何影响nanoceria不同的报告效应;以及如何将设计更安全概念应用于nanoceria?它聚焦于人类nanoceria暴露、摄取、处置、持久性及由此产生的不良反应的最相关途径。文中讨论了肺部、口腔、皮肤和眼部局部暴露途径以及静脉途径,因为后者为nanoceria一旦进入血液后的药代动力学归宿提供了参考。进入血液的nanoceria主要分布于单核吞噬系统器官。现有数据表明,nanoceria的分布受剂量、形状或给药方案的影响不大。吸入暴露途径受到了极大关注。nanoceria从肺部向身体其他部位的分布不到沉积剂量的1%,从胃肠道的分布甚至更少。细胞内的nanoceria和器官负担至少持续数月,表明清除率非常低。nanoceria的急性毒性非常低。然而,大剂量/累积剂量会在肺部和肝脏产生肉芽肿,并在肺部导致纤维化。包括遗传毒性在内的毒性会随着暴露时间增加;这些效应消失缓慢,可能是由于nanoceria的生物持久性。nanoceria可能通过氧化应激发挥毒性作用。在暴露部位远端观察到的不良反应可能是由于nanoceria的转运或释放的生物分子所致。一个例子是,在大脑中氧化应激指标升高,而此时大脑中nanoceria含量并不明显。nanoceria可能在生物环境中改变其性质,并导致生物分子发生变化。毒性增加与更大的表面铈有关,随着粒径减小和表面积与体积之比增加,这一点变得更加重要。鉴于其生物持久性以及由此导致的毒性随时间增加,长期暴露于低水平nanoceria最终可能导致不良健康影响,存在这样的风险。这篇批判性综述为研究提供了建议,以解决nanoceria归宿和不良反应的诸多未知问题。